Study Type of drug Reason of medication Mean age of
medication use
(months) 		Implants in control group Implants in study group Implant survival rate
in control group 		Implant survival rate
in study group 		Mean age of follow-up
(months)
Rugani et al. [31] Iv BP
(ibandronate) 		Osteoporosis 12 - 2 - 100% 16
Sverzut et al. [32] Iv BP (zoledronic acid) Breast cancer 72 - 3 + 3 - 0% 18 + 6
Siebert et al. [33] Iv BP (zoledronic acid) Osteoporosis 30 60 60 100% 100% 12
Lazarovicia et al. [34] Oral BP (alendronate) Osteoporosis
breast, prostate cancer, multiple myeloma 		68 - 11 patients - 7 patients
(63%) 		11.4
Iv BP (zoledronic acid/
pamidronate) 		68 16
patients 		5 patients
(31%)
Torres et al. [35] Oral BP
(Risedronate) 		Paget's disease 84 - 6 - 100% 48
Shabestari et al. [36] Oral BP (alendronate) Osteoporosis 20.5 - 46 - 100% 51.6
Bell and Bell [37] Oral BP
(alendronate/ risedronate/
ibandronate) 		Osteoporosis From 6 to 132 734 100 96.5% 95% 37.2
Fugazzotto et al. [38] Oral BP
(alendronate/
risedronate) 		Osteoporosis 39.6 - 169 - 100% 18.2
Jeffcoat [39] Oral BP
(alendronate/
risendronate) 		Osteoporosis 36 108 102 99.2% 100% 36

aLazarovici et al. [34] case concluded patients that already showed with implant-related BRONJ. Antibiotic therapy and canceling BP medication was the treatment strategy. And implant survival rate after the treatment was 63% (Intraorally medicated patients) and 31% (intravenously medicated patients).
Iv = intravenous; BP = bisphosphonates.